logo
ManageEngine Adds Native Intelligence and Advanced Automation Capabilities to Its Unified PAM Platform

ManageEngine Adds Native Intelligence and Advanced Automation Capabilities to Its Unified PAM Platform

Business Wire05-05-2025

AUSTIN, Texas--(BUSINESS WIRE)-- ManageEngine, a division of Zoho Corporation and a leading provider of enterprise IT management solutions, today announced that it has added AI-powered enhancements—featuring intelligent least privilege access and risk remediation policy recommendations—to its privileged access management platform, PAM360. A new privileged task automation module enabled by Qntrl, Zoho's unified workflow orchestration platform, has also been introduced. Together, these newly added capabilities help enterprises automate enterprise-wide administrative routines, enforce least privilege at scale with intelligent, context-aware controls and reduce security risks through automated remediation.
AI-Governed Least Privilege Access
Traditional PAM models, which rely on static policies and manual processes, often operate without sufficient context. This can result in excessive permissions, entitlement drift, and configuration errors. To address these challenges, organizations should adopt an adaptive, context-driven approach to privileged access management—one that leverages AI to enable dynamic, risk-based access control. In fact, according to ManageEngine's 2024 Identity Security Insights, 68% of the respondents are looking for AI-driven improvements in risk-based access control.
"Today's hybrid, multi-cloud environments have led to an explosion of human and non-human identities, creating complex access workflows and rampant privilege sprawl. To tackle this, organizations require dynamic policies that can intelligently enforce the principle of least privilege across their identity stack. With the AI-driven CIEM module in PAM360, IT security teams can now generate intelligent least privilege policies, proactively flag risky entitlements and automate remediation, helping enterprises close critical identity security gaps before they're exploited," said Ramanathan Kannabiran, director of product management at ManageEngine.
PAM360's CIEM module now features AI-generated least privilege policies, automated remediation of shadow admin risks and real-time access and session summaries. These AI-driven capabilities help organizations proactively tackle access sprawl and misconfigurations in hybrid environments with minimal manual effort.
Orchestrating Privileged Operations With Zero-Touch Controls
Business workflows that leverage RPA and script-based automation often rely on manual access provisioning, resulting in delayed execution and increased overhead, leading to potential security gaps. Modern IT teams need dynamic controls that can streamline on-demand access within these automated workflows and strengthen the security posture of the organization.
According to Kannabiran, 'Privileged task automation in PAM360 eliminates the need for administrators to manually grant and revoke necessary access privileges for every automated routine. Access is provisioned just in time, based on the task context, and revoked automatically once the task ends. This not only preserves admin bandwidth, but also reduces the risk of privilege misuse caused by excessive or standing access."
Powered by Qntrl, PAM360 brings native automation capabilities that eliminate the need for third-party tools. Its deep integration within the Zoho ecosystem enables seamless orchestration of privileged access workflows—enhancing efficiency without compromising security. PAM360 streamlines vendor access with automated onboarding and offboarding, provisions ephemeral, just-in-time access with fine-grained, time-bound controls, and ensures a secure, hands-free transfer of privileged data—delivering speed, consistency and reduced risk across the board.
About ManageEngine PAM360
PAM360 is ManageEngine's unified privileged access management platform that helps IT teams enforce strict governance on access pathways to critical corporate assets. With a holistic approach to privileged access security, PAM360 caters to core PAM requirements and facilitates contextual integration with multiple other IT management tools, resulting in deeper insights, meaningful inferences, and quicker remedies. More than 5,000 global organizations and over one million administrators trust PAM360 with their PAM needs. To learn more about PAM360 and its enterprise-ready capabilities, please visit https://mnge.it/pam360.
About ManageEngine
ManageEngine is a division of Zoho Corporation and a leading provider of IT management solutions for organizations across the world. With a powerful, flexible, and AI-powered digital enterprise management platform, we help businesses get their work done from anywhere and everywhere—better, safer, and faster. To learn more, visit www.manageengine.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025

Business Wire

time17 hours ago

  • Business Wire

Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025

BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ('Avistone'), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 study Abstract Number For Publication: 8632 Session: Poster Session-Lung Cancer- Non-Small Cell Metastatic Location: Poster Board, 112 Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common 'off-target' mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ('Avistone') is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.

BIOSIG TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of BioSig Technologies, Inc.
BIOSIG TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of BioSig Technologies, Inc.

Business Wire

time19 hours ago

  • Business Wire

BIOSIG TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of BioSig Technologies, Inc.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of BioSig Technologies, Inc. (NasdaqCM: BSGM) and Streamex Exchange Corporation. Upon closing of the proposed transaction, current BioSig shareholders and holders of common stock equivalents will hold 25% of the fully diluted BioSig common stock outstanding. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to BioSig shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit

SIGNING DAY SPORTS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Signing Day Sports, Inc.
SIGNING DAY SPORTS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Signing Day Sports, Inc.

Business Wire

time20 hours ago

  • Business Wire

SIGNING DAY SPORTS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Signing Day Sports, Inc.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of Signing Day Sports, Inc. (NYSE: SGN) and One Blockchain LLC. Upon closing of the proposed transaction, Signing Day shareholders are expected to own approximately 8.5% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Signing Day shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store